{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:53:13Z","timestamp":1794621193924,"version":"4.9.1"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2025R1A2C2008672"],"award-info":[{"award-number":["NRF-2025R1A2C2008672"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00217123"],"award-info":[{"award-number":["RS-2023-00217123"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD44, a multifunctional transmembrane glycoprotein, is not only a bystander but also a crucial driver of cancer progression that promotes cancer stem cell maintenance, metastasis, and resistance to therapy. Therefore, CD44 is recognized as a promising therapeutic target in advanced malignancies. Here, we discuss its unique features, such as its structural diversity, which arise from alternative splicing and the post-translational modifications of cleavage and phosphorylation. In addition, we discuss the function of CD44 as a multivalent cell adhesion receptor for extracellular matrix components, including hyaluronic acid, fibronectin, osteopontin, and TSG6, thereby regulating lymphocyte activation, cell\u2013cell interactions, cell adhesion, and migration within the extracellular matrix. Moreover, the emerging role of CD44 as a co-receptor of receptor tyrosine kinases such as epidermal growth factor receptor, c-MET, and vascular endothelial growth factor receptor 2 is highlighted to elucidate the contribution of CD44 to malignant signaling networks. We also discuss its potential as a therapeutic target in advanced cancers, particularly its applications in unconjugated antibodies, antibody\u2013drug conjugates, peptide-based inhibitors, and chimeric antigen receptor-T cell therapies. We conclude by addressing the limitations observed in clinical studies and outlining promising opportunities for future development.<\/jats:p>","DOI":"10.1038\/s12276-026-01797-x","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:26:04Z","timestamp":1785831964000},"page":"2451-2469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multifaceted roles of CD44 in cancer progression and targeted therapeutic strategies"],"prefix":"10.1038","volume":"58","author":[{"given":"Hyun-Ji","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-To","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-3472","authenticated-orcid":false,"given":"Hyungshin","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1797_CR1","doi-asserted-by":"publisher","first-page":"7023","DOI":"10.1016\/S0021-9258(19)69093-9","volume":"256","author":"E Hughes","year":"1981","unstructured":"Hughes, E., Mengod, G. & August, J. Murine cell surface glycoproteins. Characterization of a major component of 80,000 daltons as a polymorphic differentiation antigen of mesenchymal cells. J Biol Chem 256, 7023\u20137027 (1981).","journal-title":"J Biol Chem"},{"key":"1797_CR2","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1016\/S0021-9258(19)81103-1","volume":"257","author":"WG Carter","year":"1982","unstructured":"Carter, W. G. The cooperative role of the transformation-sensitive glycoproteins, GP140 and fibronectin, in cell attachment and spreading. J Biol Chem 257, 3249\u20133257 (1982).","journal-title":"J Biol Chem"},{"key":"1797_CR3","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1083\/jcb.105.4.1873","volume":"105","author":"EA Wayner","year":"1987","unstructured":"Wayner, E. A. & Carter, W. G. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J Cell Biol 105, 1873\u20131884 (1987).","journal-title":"J Cell Biol"},{"key":"1797_CR4","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1016\/S0021-9258(18)68908-2","volume":"263","author":"WG Carter","year":"1988","unstructured":"Carter, W. G. & Wayner, E. A. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 263, 4193\u20134201 (1988).","journal-title":"J Biol Chem"},{"key":"1797_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1126\/science.3726548","volume":"233","author":"S Jalkanen","year":"1986","unstructured":"Jalkanen, S., Steere, A. C., Fox, R. I. & Butcher, E. C. A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium. Science 233, 556\u2013558 (1986).","journal-title":"Science"},{"key":"1797_CR6","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/0092-8674(89)90639-9","volume":"56","author":"LA Goldstein","year":"1989","unstructured":"Goldstein, L. A. et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 56, 1063\u20131072 (1989).","journal-title":"Cell"},{"key":"1797_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood.V75.3.589.589","volume":"75","author":"DM Lewinsohn","year":"1990","unstructured":"Lewinsohn, D. M., Nagler, A., Ginzton, N., Greenberg, P. & Butcher, E. C. Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 75, 589\u2013595 (1990).","journal-title":"Blood"},{"key":"1797_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","volume":"61","author":"A Aruffo","year":"1990","unstructured":"Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303\u20131313 (1990).","journal-title":"Cell"},{"key":"1797_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1126\/science.271.5248.509","volume":"271","author":"GF Weber","year":"1996","unstructured":"Weber, G. F., Ashkar, S., Glimcher, M. J. & Cantor, H. Receptor\u2013ligand interaction between CD44 and osteopontin (Eta-1). Science 271, 509\u2013512 (1996).","journal-title":"Science"},{"key":"1797_CR10","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1074\/jbc.R100036200","volume":"277","author":"AJ Day","year":"2002","unstructured":"Day, A. J. & Prestwich, G. D. Hyaluronan-binding proteins: tying up the giant. J Biol Chem 277, 4585\u20134588 (2002).","journal-title":"J Biol Chem"},{"key":"1797_CR11","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983\u20133988 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1797_CR12","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1158\/1078-0432.CCR-08-1034","volume":"14","author":"L Du","year":"2008","unstructured":"Du, L. et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14, 6751\u20136760 (2008).","journal-title":"Clin Cancer Res"},{"key":"1797_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/mp.51.4.191","volume":"51","author":"RJ Sneath","year":"1998","unstructured":"Sneath, R. J. & Mangham, D. C. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51, 191\u2013200 (1998).","journal-title":"Mol Pathol"},{"key":"1797_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.0.CO;2-G","volume":"39","author":"J Bajorath","year":"2000","unstructured":"Bajorath, J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins 39, 103\u2013111 (2000).","journal-title":"Proteins"},{"key":"1797_CR15","doi-asserted-by":"publisher","first-page":"12160","DOI":"10.1073\/pnas.89.24.12160","volume":"89","author":"GR Screaton","year":"1992","unstructured":"Screaton, G. R. et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89, 12160\u201312164 (1992).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1797_CR16","doi-asserted-by":"publisher","first-page":"12235","DOI":"10.1016\/S0021-9258(18)31376-0","volume":"268","author":"GR Screaton","year":"1993","unstructured":"Screaton, G. R., Bell, M. V., Bell, J. I. & Jackson, D. G. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268, 12235\u201312238 (1993).","journal-title":"J Biol Chem"},{"key":"1797_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/mp.52.4.189","volume":"52","author":"S Goodison","year":"1999","unstructured":"Goodison, S., Urquidi, V. & Tarin, D. CD44 cell adhesion molecules. Mol Pathol 52, 189\u2013196 (1999).","journal-title":"Mol Pathol"},{"key":"1797_CR18","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.1074\/jbc.M108654200","volume":"277","author":"H Jiang","year":"2002","unstructured":"Jiang, H. et al. A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells. J Biol Chem 277, 10531\u201310538 (2002).","journal-title":"J Biol Chem"},{"key":"1797_CR19","doi-asserted-by":"publisher","first-page":"e0138137","DOI":"10.1371\/journal.pone.0138137","volume":"10","author":"H Kellett-Clarke","year":"2015","unstructured":"Kellett-Clarke, H., Stegmann, M., Barclay, A. N. & Metcalfe, C. CD44 Binding to hyaluronic acid is redox regulated by a labile disulfide bond in the hyaluronic acid binding site. PLoS ONE 10, e0138137 (2015).","journal-title":"PLoS ONE"},{"key":"1797_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1083\/jcb.200108159","volume":"155","author":"I Okamoto","year":"2001","unstructured":"Okamoto, I. et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155, 755\u2013762 (2001).","journal-title":"J Cell Biol"},{"key":"1797_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1101\/gr.3.2.100","volume":"3","author":"DH van Weering","year":"1993","unstructured":"van Weering, D. H., Baas, P. D. & Bos, J. L. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 3, 100\u2013106 (1993).","journal-title":"PCR Methods Appl"},{"key":"1797_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1101\/gad.241968.114","volume":"28","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev 28, 1191\u20131203 (2014).","journal-title":"Genes Dev"},{"key":"1797_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1172\/JCI44540","volume":"121","author":"RL Brown","year":"2011","unstructured":"Brown, R. L. et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial\u2013mesenchymal transition and breast cancer progression. J Clin Invest 121, 1064\u20131074 (2011).","journal-title":"J Clin Invest"},{"key":"1797_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00018-020-03544-5","volume":"78","author":"Q Chen","year":"2021","unstructured":"Chen, Q. et al. TGF-beta1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. Cell Mol Life Sci 78, 949\u2013962 (2021).","journal-title":"Cell Mol Life Sci"},{"key":"1797_CR25","doi-asserted-by":"publisher","first-page":"36435","DOI":"10.1074\/jbc.M112.397125","volume":"287","author":"LM Reinke","year":"2012","unstructured":"Reinke, L. M., Xu, Y. & Cheng, C. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial\u2013mesenchymal transition. J Biol Chem 287, 36435\u201336442 (2012).","journal-title":"J Biol Chem"},{"key":"1797_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/sj.bmt.1700940","volume":"20","author":"S Neu","year":"1997","unstructured":"Neu, S. et al. Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses. Bone Marrow Transplant 20, 593\u2013598 (1997).","journal-title":"Bone Marrow Transplant"},{"key":"1797_CR27","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.4049\/jimmunol.151.11.6490","volume":"151","author":"HX Liao","year":"1993","unstructured":"Liao, H. X. et al. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. J Immunol 151, 6490\u20136499 (1993).","journal-title":"J Immunol"},{"key":"1797_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00262-003-0494-4","volume":"53","author":"KH Heider","year":"2004","unstructured":"Heider, K. H., Kuthan, H., Stehle, G. & Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53, 567\u2013579 (2004).","journal-title":"Cancer Immunol Immunother"},{"key":"1797_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s002620050329","volume":"43","author":"KH Heider","year":"1996","unstructured":"Heider, K. H. et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43, 245\u2013253 (1996).","journal-title":"Cancer Immunol Immunother"},{"key":"1797_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2015.10.020","volume":"150","author":"A Matzke-Ogi","year":"2016","unstructured":"Matzke-Ogi, A. et al. Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling. Gastroenterology 150, 513\u2013525.e10 (2016).","journal-title":"Gastroenterology"},{"key":"1797_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1084\/jem.177.4.897","volume":"177","author":"G Koopman","year":"1993","unstructured":"Koopman, G. et al. Activated human lymphocytes and aggressive non-Hodgkin\u2019s lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177, 897\u2013904 (1993).","journal-title":"J Exp Med"},{"key":"1797_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(95)90521-9","volume":"345","author":"M Kaufmann","year":"1995","unstructured":"Kaufmann, M. et al. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345, 615\u2013619 (1995).","journal-title":"Lancet"},{"key":"1797_CR33","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/1097-0142(19950301)75:5<1065::AID-CNCR2820750503>3.0.CO;2-N","volume":"75","author":"HJ Harn","year":"1995","unstructured":"Harn, H. J. et al. Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 75, 1065\u20131071 (1995).","journal-title":"Cancer"},{"key":"1797_CR34","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S0140-6736(94)90290-9","volume":"344","author":"JW Mulder","year":"1994","unstructured":"Mulder, J. W. et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344, 1470\u20131472 (1994).","journal-title":"Lancet"},{"key":"1797_CR35","doi-asserted-by":"publisher","first-page":"e0156595","DOI":"10.1371\/journal.pone.0156595","volume":"11","author":"A Sosulski","year":"2016","unstructured":"Sosulski, A. et al. CD44 splice variant v8-10 as a marker of serous ovarian cancer prognosis. PLoS ONE 11, e0156595 (2016).","journal-title":"PLoS ONE"},{"key":"1797_CR36","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1083\/jcb.115.5.1283","volume":"115","author":"RL Camp","year":"1991","unstructured":"Camp, R. L., Kraus, T. A. & Pure, E. Variations in the cytoskeletal interaction and posttranslational modification of the CD44 homing receptor in macrophages. J Cell Biol 115, 1283\u20131292 (1991).","journal-title":"J Cell Biol"},{"key":"1797_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep08926","volume":"5","author":"HS Lee","year":"2015","unstructured":"Lee, H. S., Qi, Y. & Im, W. Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study. Sci Rep 5, 8926 (2015).","journal-title":"Sci Rep"},{"key":"1797_CR38","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1083\/jcb.132.6.1199","volume":"132","author":"A Bartolazzi","year":"1996","unstructured":"Bartolazzi, A., Nocks, A., Aruffo, A., Spring, F. & Stamenkovic, I. Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol 132, 1199\u20131208 (1996).","journal-title":"J Cell Biol"},{"key":"1797_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1097-2765(04)00080-2","volume":"13","author":"P Teriete","year":"2004","unstructured":"Teriete, P. et al. Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell 13, 483\u2013496 (2004).","journal-title":"Mol Cell"},{"key":"1797_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151360","volume":"102","author":"Q Cheng","year":"2023","unstructured":"Cheng, Q. et al. N-glycosylation at N57\/100\/110 affects CD44s localization, function and stability in hepatocellular carcinoma. Eur J Cell Biol 102, 151360 (2023).","journal-title":"Eur J Cell Biol"},{"key":"1797_CR41","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1083\/jcb.131.6.1623","volume":"131","author":"KL Bennett","year":"1995","unstructured":"Bennett, K. L. et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol 131, 1623\u20131633 (1995).","journal-title":"J Cell Biol"},{"key":"1797_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1083\/jcb.128.4.673","volume":"128","author":"DG Jackson","year":"1995","unstructured":"Jackson, D. G. et al. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 128, 673\u2013685 (1995).","journal-title":"J Cell Biol"},{"key":"1797_CR43","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1002\/j.1460-2075.1992.tb05578.x","volume":"11","author":"SJ Neame","year":"1992","unstructured":"Neame, S. J. & Isacke, C. M. Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeletal interaction in epithelial cells. EMBO J 11, 4733\u20134738 (1992).","journal-title":"EMBO J"},{"key":"1797_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1042\/bj3570843","volume":"357","author":"CA Lewis","year":"2001","unstructured":"Lewis, C. A., Townsend, P. A. & Isacke, C. M. Ca(2+)\/calmodulin-dependent protein kinase mediates the phosphorylation of CD44 required for cell migration on hyaluronan. Biochem J 357, 843\u2013850 (2001).","journal-title":"Biochem J"},{"key":"1797_CR45","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1038\/sj.onc.1209724","volume":"25","author":"G Tzircotis","year":"2006","unstructured":"Tzircotis, G., Thorne, R. F. & Isacke, C. M. Directional sensing of a phorbol ester gradient requires CD44 and is regulated by CD44 phosphorylation. Oncogene 25, 7401\u20137410 (2006).","journal-title":"Oncogene"},{"key":"1797_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/ncb797","volume":"4","author":"JW Legg","year":"2002","unstructured":"Legg, J. W., Lewis, C. A., Parsons, M., Ng, T. & Isacke, C. M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol 4, 399\u2013407 (2002).","journal-title":"Nat Cell Biol"},{"key":"1797_CR47","doi-asserted-by":"publisher","first-page":"26308","DOI":"10.18632\/oncotarget.4763","volume":"6","author":"AK Ravindranath","year":"2015","unstructured":"Ravindranath, A. K. et al. CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget 6, 26308\u201326321 (2015).","journal-title":"Oncotarget"},{"key":"1797_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.153.5.893","volume":"153","author":"M Kajita","year":"2001","unstructured":"Kajita, M. et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153, 893\u2013904 (2001).","journal-title":"J Cell Biol"},{"key":"1797_CR49","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1093\/emboj\/cdf411","volume":"21","author":"H Mori","year":"2002","unstructured":"Mori, H. et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 21, 3949\u20133959 (2002).","journal-title":"EMBO J"},{"key":"1797_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1101\/gad.13.1.35","volume":"13","author":"Q Yu","year":"1999","unstructured":"Yu, Q. & Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13, 35\u201348 (1999).","journal-title":"Genes Dev"},{"key":"1797_CR51","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1042\/BCJ20200628","volume":"478","author":"G Yosef","year":"2021","unstructured":"Yosef, G., Hayun, H. & Papo, N. Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy. Biochem J 478, 1139\u20131157 (2021).","journal-title":"Biochem J"},{"key":"1797_CR52","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-03-3502","volume":"64","author":"H Nakamura","year":"2004","unstructured":"Nakamura, H. et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res 64, 876\u2013882 (2004).","journal-title":"Cancer Res"},{"key":"1797_CR53","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200310024","volume":"165","author":"O Nagano","year":"2004","unstructured":"Nagano, O. et al. Cell\u2013matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165, 893\u2013902 (2004).","journal-title":"J Cell Biol"},{"key":"1797_CR54","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/jid.2008.323","volume":"129","author":"U Anderegg","year":"2009","unstructured":"Anderegg, U. et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 129, 1471\u20131482 (2009).","journal-title":"J Invest Dermatol"},{"key":"1797_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep37464","volume":"6","author":"LM Parra","year":"2016","unstructured":"Parra, L. M. et al. Growth factor and co-receptor release by structural regulation of substrate metalloprotease accessibility. Sci Rep 6, 37464 (2016).","journal-title":"Sci Rep"},{"key":"1797_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/cam4.147","volume":"2","author":"P Kamarajan","year":"2013","unstructured":"Kamarajan, P. et al. 44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC. Cancer Med 2, 793\u2013802 (2013).","journal-title":"Cancer Med"},{"key":"1797_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1026810","volume":"10","author":"B Wohner","year":"2023","unstructured":"Wohner, B. et al. Proteolysis of CD44 at the cell surface controls a downstream protease network. Front Mol Biosci 10, 1026810 (2023).","journal-title":"Front Mol Biosci"},{"key":"1797_CR58","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/sj.onc.1206298","volume":"22","author":"D Murakami","year":"2003","unstructured":"Murakami, D. et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22, 1511\u20131516 (2003).","journal-title":"Oncogene"},{"key":"1797_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2020.05.019","volume":"105","author":"G Guner","year":"2020","unstructured":"Guner, G. & Lichtenthaler, S. F. The substrate repertoire of gamma-secretase\/presenilin. Semin Cell Dev Biol 105, 27\u201342 (2020).","journal-title":"Semin Cell Dev Biol"},{"key":"1797_CR60","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.7150\/ijbs.115097","volume":"21","author":"HJ Oh","year":"2025","unstructured":"Oh, H. J., Min, G. H., Kim, D. E., Shin, S. B. & Yim, H. TSG6 promotes epithelial-mesenchymal transition and tumor-associated macrophage polarization through Smad2\/3 and MAPK signaling by facilitating TSG6-CD44-TGFbetaR1 or EGFR complex formation. Int J Biol Sci 21, 4701\u20134718 (2025).","journal-title":"Int J Biol Sci"},{"key":"1797_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1091\/mbc.e02-06-0354","volume":"14","author":"MA Chellaiah","year":"2003","unstructured":"Chellaiah, M. A. et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14, 173\u2013189 (2003).","journal-title":"Mol Biol Cell"},{"key":"1797_CR62","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1083\/jcb.116.3.817","volume":"116","author":"S Jalkanen","year":"1992","unstructured":"Jalkanen, S. & Jalkanen, M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 116, 817\u2013825 (1992).","journal-title":"J Cell Biol"},{"key":"1797_CR63","doi-asserted-by":"publisher","first-page":"25745","DOI":"10.1074\/jbc.M313319200","volume":"279","author":"J Lesley","year":"2004","unstructured":"Lesley, J. et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem 279, 25745\u201325754 (2004).","journal-title":"J Biol Chem"},{"key":"1797_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2019.02.002","volume":"78\u201379","author":"S Garantziotis","year":"2019","unstructured":"Garantziotis, S. & Savani, R. C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol 78\u201379, 1\u201310 (2019).","journal-title":"Matrix Biol"},{"key":"1797_CR65","doi-asserted-by":"publisher","first-page":"43550","DOI":"10.1074\/jbc.M308199200","volume":"278","author":"M Takeda","year":"2003","unstructured":"Takeda, M. et al. Hyaluronan recognition mode of CD44 revealed by cross-saturation and chemical shift perturbation experiments. J Biol Chem 278, 43550\u201343555 (2003).","journal-title":"J Biol Chem"},{"key":"1797_CR66","doi-asserted-by":"publisher","first-page":"e1005663","DOI":"10.1371\/journal.pcbi.1005663","volume":"13","author":"J Vuorio","year":"2017","unstructured":"Vuorio, J., Vattulainen, I. & Martinez-Seara, H. Atomistic fingerprint of hyaluronan\u2013CD44 binding. PLoS Comput Biol 13, e1005663 (2017).","journal-title":"PLoS Comput Biol"},{"key":"1797_CR67","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fimmu.2015.00201","volume":"6","author":"S Misra","year":"2015","unstructured":"Misra, S., Hascall, V. C., Markwald, R. R. & Ghatak, S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol 6, 201 (2015).","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"1797_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/03008200390152061","volume":"44","author":"LW Fisher","year":"2003","unstructured":"Fisher, L. W. & Fedarko, N. S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44(Suppl 1), 33\u201340 (2003).","journal-title":"Connect Tissue Res"},{"key":"1797_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2014.01.005","volume":"14","author":"A Pietras","year":"2014","unstructured":"Pietras, A. et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14, 357\u2013369 (2014).","journal-title":"Cell Stem Cell"},{"key":"1797_CR70","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1158\/1078-0432.CCR-12-2788","volume":"19","author":"G Rao","year":"2013","unstructured":"Rao, G. et al. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin\/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res 19, 785\u2013797 (2013).","journal-title":"Clin Cancer Res"},{"key":"1797_CR71","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/carcin\/bgg139","volume":"24","author":"C Gao","year":"2003","unstructured":"Gao, C. et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24, 1871\u20131878 (2003).","journal-title":"Carcinogenesis"},{"key":"1797_CR72","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.bi.57.070188.002111","volume":"57","author":"E Ruoslahti","year":"1988","unstructured":"Ruoslahti, E. Fibronectin and its receptors. Annu Rev Biochem 57, 375\u2013413 (1988).","journal-title":"Annu Rev Biochem"},{"key":"1797_CR73","doi-asserted-by":"publisher","first-page":"36762","DOI":"10.18632\/oncotarget.5461","volume":"6","author":"S McFarlane","year":"2015","unstructured":"McFarlane, S., McFarlane, C., Montgomery, N., Hill, A. & Waugh, D. J. CD44-mediated activation of \u03b15\u03b21-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices. Oncotarget 6, 36762\u201336773 (2015).","journal-title":"Oncotarget"},{"key":"1797_CR74","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0171-2985(97)80067-8","volume":"196","author":"L Cao","year":"1996","unstructured":"Cao, L. et al. Binding of human leukocytes to fibronectin is augmented by an anti-CD44 mAb (TL-1) and blocked by another anti-CD44 mAb (Hermes-3) but not by anti-VLA-4\/VLA-5 mAbs. Immunobiology 196, 504\u2013512 (1996).","journal-title":"Immunobiology"},{"key":"1797_CR75","doi-asserted-by":"publisher","first-page":"22764","DOI":"10.1074\/jbc.M100666200","volume":"276","author":"DJ Mahoney","year":"2001","unstructured":"Mahoney, D. J., Blundell, C. D. & Day, A. J. Mapping the hyaluronan-binding site on the link module from human tumor necrosis factor-stimulated gene-6 by site-directed mutagenesis. J Biol Chem 276, 22764\u201322771 (2001).","journal-title":"J Biol Chem"},{"key":"1797_CR76","doi-asserted-by":"publisher","first-page":"425","DOI":"10.5483\/BMBRep.2020.53.8.268","volume":"53","author":"S Wang","year":"2020","unstructured":"Wang, S., Kim, J., Lee, C. & Jung, Y. Tumor necrosis factor-inducible gene 6 interacts with CD44, which is involved in fate-change of hepatic stellate cells. BMB Rep 53, 425\u2013430 (2020).","journal-title":"BMB Rep"},{"key":"1797_CR77","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41388-019-1023-z","volume":"39","author":"SB Shin","year":"2020","unstructured":"Shin, S. B., Jang, H. R., Xu, R., Won, J. Y. & Yim, H. Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer. Oncogene 39, 767\u2013785 (2020).","journal-title":"Oncogene"},{"key":"1797_CR78","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.7150\/ijbs.69178","volume":"18","author":"B Liu","year":"2022","unstructured":"Liu, B. et al. TSG-6 promotes cancer cell aggressiveness in a CD44-dependent manner and reprograms normal fibroblasts to create a pro-metastatic microenvironment in colorectal cancer. Int J Biol Sci 18, 1677\u20131694 (2022).","journal-title":"Int J Biol Sci"},{"key":"1797_CR79","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.oraloncology.2012.11.009","volume":"49","author":"A Perez","year":"2013","unstructured":"Perez, A. et al. CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression. Oral Oncol 49, 306\u2013313 (2013).","journal-title":"Oral Oncol"},{"key":"1797_CR80","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/archotol.132.7.771","volume":"132","author":"SJ Wang","year":"2006","unstructured":"Wang, S. J. & Bourguignon, L. Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 132, 771\u2013778 (2006).","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1797_CR81","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3892\/ijo.2016.3639","volume":"49","author":"H Xu","year":"2016","unstructured":"Xu, H. et al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol 49, 1343\u20131350 (2016).","journal-title":"Int J Oncol"},{"key":"1797_CR82","first-page":"1783","volume":"45","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild\u2011type non\u2011small\u2011cell lung cancer cells. Int J Mol Med 45, 1783\u20131792 (2020).","journal-title":"Int J Mol Med"},{"key":"1797_CR83","doi-asserted-by":"publisher","first-page":"17618","DOI":"10.1074\/jbc.M111.226563","volume":"286","author":"S Meran","year":"2011","unstructured":"Meran, S. et al. Hyaluronan facilitates transforming growth factor-beta1-dependent proliferation via CD44 and epidermal growth factor receptor interaction. J Biol Chem 286, 17618\u201317630 (2011).","journal-title":"J Biol Chem"},{"key":"1797_CR84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/00129039-200203000-00006","volume":"10","author":"M Wobus","year":"2002","unstructured":"Wobus, M. et al. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol 10, 34\u201339 (2002).","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1797_CR85","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/s41388-017-0030-1","volume":"37","author":"I Morath","year":"2018","unstructured":"Morath, I. et al. Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer. Oncogene 37, 1472\u20131484 (2018).","journal-title":"Oncogene"},{"key":"1797_CR86","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1182\/blood-2009-04-219204","volume":"114","author":"M Tremmel","year":"2009","unstructured":"Tremmel, M. et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114, 5236\u20135244 (2009).","journal-title":"Blood"},{"key":"1797_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20150093","volume":"35","author":"Y Volz","year":"2015","unstructured":"Volz, Y. et al. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6. Biosci Rep 35, 1\u201316 (2015).","journal-title":"Biosci Rep"},{"key":"1797_CR88","doi-asserted-by":"publisher","first-page":"39703","DOI":"10.1074\/jbc.M204320200","volume":"277","author":"LY Bourguignon","year":"2002","unstructured":"Bourguignon, L. Y., Singleton, P. A., Zhu, H. & Zhou, B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 277, 39703\u201339712 (2002).","journal-title":"J Biol Chem"},{"key":"1797_CR89","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1101\/gad.319889.118","volume":"33","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev 33, 166\u2013179 (2019).","journal-title":"Genes Dev"},{"key":"1797_CR90","doi-asserted-by":"publisher","first-page":"28670","DOI":"10.18632\/oncotarget.8764","volume":"7","author":"J Park","year":"2016","unstructured":"Park, J. et al. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. Oncotarget 7, 28670\u201328683 (2016).","journal-title":"Oncotarget"},{"key":"1797_CR91","doi-asserted-by":"publisher","first-page":"34936","DOI":"10.1074\/jbc.C600138200","volume":"281","author":"S Misra","year":"2006","unstructured":"Misra, S., Toole, B. P. & Ghatak, S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 281, 34936\u201334941 (2006).","journal-title":"J Biol Chem"},{"key":"1797_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05103-1","volume":"13","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching. Cell Death Dis 13, 682 (2022).","journal-title":"Cell Death Dis"},{"key":"1797_CR93","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41417-025-00937-1","volume":"32","author":"S Li","year":"2025","unstructured":"Li, S. et al. Combined downregulation of TGF-beta1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit. Cancer Gene Ther 32, 884\u2013898 (2025).","journal-title":"Cancer Gene Ther"},{"key":"1797_CR94","doi-asserted-by":"publisher","first-page":"18995","DOI":"10.1074\/jbc.M111.318774","volume":"287","author":"KE Miletti-Gonzalez","year":"2012","unstructured":"Miletti-Gonzalez, K. E. et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem 287, 18995\u201319007 (2012).","journal-title":"J Biol Chem"},{"key":"1797_CR95","doi-asserted-by":"publisher","first-page":"8709","DOI":"10.18632\/oncotarget.3325","volume":"6","author":"Y Cho","year":"2015","unstructured":"Cho, Y. et al. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 6, 8709\u20138721 (2015).","journal-title":"Oncotarget"},{"key":"1797_CR96","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1541-7786.MCR-09-0237","volume":"9","author":"JW Cain","year":"2011","unstructured":"Cain, J. W. et al. Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res 9, 637\u2013647 (2011).","journal-title":"Mol Cancer Res"},{"key":"1797_CR97","first-page":"1381","volume":"54","author":"MB Penno","year":"1994","unstructured":"Penno, M. B. et al. Expression of CD44 in human lung tumors. Cancer Res 54, 1381\u20131387 (1994).","journal-title":"Cancer Res"},{"key":"1797_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2025.102028","volume":"81","author":"E Alaei","year":"2025","unstructured":"Alaei, E. et al. The clinicopathologic and prognostic value of CD44 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Mol Cell Probes 81, 102028 (2025).","journal-title":"Mol Cell Probes"},{"key":"1797_CR99","first-page":"5627","volume":"15","author":"B Hu","year":"2018","unstructured":"Hu, B. et al. CD44 promotes cell proliferation in non-small cell lung cancer. Oncol Lett 15, 5627\u20135633 (2018).","journal-title":"Oncol Lett"},{"key":"1797_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13164057","volume":"13","author":"YY Wang","year":"2021","unstructured":"Wang, Y. Y. et al. CD44 promotes lung cancer cell metastasis through ERK-ZEB1 Signaling. Cancers (Basel) 13, 1\u201315 (2021).","journal-title":"Cancers (Basel)"},{"key":"1797_CR101","doi-asserted-by":"publisher","first-page":"e14062","DOI":"10.1371\/journal.pone.0014062","volume":"5","author":"EL Leung","year":"2010","unstructured":"Leung, E. L. et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE 5, e14062 (2010).","journal-title":"PLoS ONE"},{"key":"1797_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01671-4","volume":"20","author":"C Zhang","year":"2020","unstructured":"Zhang, C., Wang, H., Wang, X., Zhao, C. & Wang, H. CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell Int 20, 583 (2020).","journal-title":"Cancer Cell Int"},{"key":"1797_CR103","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0043-1772459","volume":"10","author":"L Kavitha","year":"2023","unstructured":"Kavitha, L. et al. Expression of CD44 in head and neck squamous cell carcinoma \u2014 an in-silico study. Glob Med Genet 10, 221\u2013228 (2023).","journal-title":"Glob Med Genet"},{"key":"1797_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-15","volume":"14","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 14, 15 (2014).","journal-title":"BMC Cancer"},{"key":"1797_CR105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/039463201402700304","volume":"27","author":"M Athanassiou-Papaefthymiou","year":"2014","unstructured":"Athanassiou-Papaefthymiou, M. et al. Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol 27, 337\u2013349 (2014).","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1797_CR106","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.ajpath.2010.11.077","volume":"178","author":"SJ Wang","year":"2011","unstructured":"Wang, S. J. & Bourguignon, L. Y. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 178, 956\u2013963 (2011).","journal-title":"Am J Pathol"},{"key":"1797_CR107","first-page":"431","volume":"9","author":"H Xu","year":"2016","unstructured":"Xu, H. et al. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther 9, 431\u2013444 (2016).","journal-title":"Onco Targets Ther"},{"key":"1797_CR108","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.2147\/OTT.S156101","volume":"11","author":"GL Qiao","year":"2018","unstructured":"Qiao, G. L., Song, L. N., Deng, Z. F., Chen, Y. & Ma, L. J. Prognostic value of CD44v6 expression in breast cancer: a meta-analysis. Onco Targets Ther 11, 5451\u20135457 (2018).","journal-title":"Onco Targets Ther"},{"key":"1797_CR109","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.18632\/oncotarget.3410","volume":"6","author":"S McFarlane","year":"2015","unstructured":"McFarlane, S. et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget 6, 11465\u201311476 (2015).","journal-title":"Oncotarget"},{"key":"1797_CR110","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/0008-5472.CAN-16-2545","volume":"77","author":"S Liu","year":"2017","unstructured":"Liu, S. & Cheng, C. Akt signaling is sustained by a CD44 splice isoform-mediated positive feedback loop. Cancer Res 77, 3791\u20133801 (2017).","journal-title":"Cancer Res"},{"key":"1797_CR111","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/21655979.2020.1765500","volume":"11","author":"Y Hu","year":"2020","unstructured":"Hu, Y., Zhang, Y., Gao, J., Lian, X. & Wang, Y. The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data. Bioengineered 11, 572\u2013581 (2020).","journal-title":"Bioengineered"},{"key":"1797_CR112","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00432-019-03024-9","volume":"145","author":"V Anand","year":"2019","unstructured":"Anand, V. et al. CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt\/ERK\/STAT3 pathways: novel therapeutic approach. J Cancer Res Clin Oncol 145, 2649\u20132661 (2019).","journal-title":"J Cancer Res Clin Oncol"},{"key":"1797_CR113","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3892\/or.2016.5061","volume":"36","author":"K Kobayashi","year":"2016","unstructured":"Kobayashi, K. et al. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Oncol Rep 36, 2852\u20132860 (2016).","journal-title":"Oncol Rep"},{"key":"1797_CR114","first-page":"6724","volume":"8","author":"XP Li","year":"2015","unstructured":"Li, X. P., Zhang, X. W., Zheng, L. Z. & Guo, W. J. Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 8, 6724\u20136731 (2015).","journal-title":"Int J Clin Exp Pathol"},{"key":"1797_CR115","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3892\/or.2014.3245","volume":"32","author":"K Chen","year":"2014","unstructured":"Chen, K. et al. Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncol Rep 32, 755\u2013763 (2014).","journal-title":"Oncol Rep"},{"key":"1797_CR116","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-09-2505","volume":"70","author":"Y Xu","year":"2010","unstructured":"Xu, Y., Stamenkovic, I. & Yu, Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70, 2455\u20132464 (2010).","journal-title":"Cancer Res"},{"key":"1797_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14153747","volume":"14","author":"C Kolliopoulos","year":"2022","unstructured":"Kolliopoulos, C., Ali, M. M., Castillejo-Lopez, C., Heldin, C. H. & Heldin, P. CD44 depletion in glioblastoma cells suppresses growth and stemness and induces senescence. Cancers (Basel) 14, 1\u201318 (2022).","journal-title":"Cancers (Basel)"},{"key":"1797_CR118","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41420-021-00672-0","volume":"7","author":"MA Pibuel","year":"2021","unstructured":"Pibuel, M. A. et al. Antitumor effect of 4MU on glioblastoma cells is mediated by senescence induction and CD44, RHAMM and p-ERK modulation. Cell Death Discov 7, 280 (2021).","journal-title":"Cell Death Discov"},{"key":"1797_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100549","volume":"296","author":"MA Pibuel","year":"2021","unstructured":"Pibuel, M. A., Poodts, D., Diaz, M., Hajos, S. E. & Lompardia, S. L. The scrambled story between hyaluronan and glioblastoma. J Biol Chem 296, 100549 (2021).","journal-title":"J Biol Chem"},{"key":"1797_CR120","doi-asserted-by":"publisher","first-page":"32532","DOI":"10.18632\/oncotarget.8687","volume":"7","author":"N Vey","year":"2016","unstructured":"Vey, N. et al. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget 7, 32532\u201332542 (2016).","journal-title":"Oncotarget"},{"key":"1797_CR121","doi-asserted-by":"publisher","first-page":"80046","DOI":"10.18632\/oncotarget.11098","volume":"7","author":"CW Menke-van der Houven van Oordt","year":"2016","unstructured":"Menke-van der Houven van Oordt, C. W. et al. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget 7, 80046\u201380058 (2016).","journal-title":"Oncotarget"},{"key":"1797_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells14231873","volume":"14","author":"A Hirayama","year":"2025","unstructured":"Hirayama, A. et al. Therapeutic potential of an anti-CD44v6 monoclonal antibody in xenograft models of colorectal and gastric cancer. Cells 14, 1\u201314 (2025).","journal-title":"Cells"},{"key":"1797_CR123","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00262-003-0396-5","volume":"52","author":"DR Colnot","year":"2003","unstructured":"Colnot, D. R. et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 52, 576\u2013582 (2003).","journal-title":"Cancer Immunol Immunother"},{"key":"1797_CR124","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.10369","volume":"99","author":"I Verel","year":"2002","unstructured":"Verel, I. et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 99, 396\u2013402 (2002).","journal-title":"Int J Cancer"},{"key":"1797_CR125","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1241159","volume":"189","author":"S Remillard","year":"1975","unstructured":"Remillard, S., Rebhun, L. I., Howie, G. A. & Kupchan, S. M. Antimitotic activity of the potent tumor inhibitor maytansine. Science 189, 1002\u20131005 (1975).","journal-title":"Science"},{"key":"1797_CR126","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus, M. et al. Maytansine and cellular metabolites of antibody\u2013maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9, 2689\u20132699 (2010).","journal-title":"Mol Cancer Ther"},{"key":"1797_CR127","first-page":"927","volume":"30","author":"A Sauter","year":"2007","unstructured":"Sauter, A. et al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30, 927\u2013935 (2007).","journal-title":"Int J Oncol"},{"key":"1797_CR128","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","volume":"12","author":"BM Tijink","year":"2006","unstructured":"Tijink, B. M. et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12, 6064\u20136072 (2006).","journal-title":"Clin Cancer Res"},{"key":"1797_CR129","first-page":"1","volume":"12","author":"Y Kudo","year":"2023","unstructured":"Kudo, Y., Suzuki, H., Tanaka, T., Kaneko, M. K. & Kato, Y. Development of a novel anti-CD44 variant 5 monoclonal antibody C(44)Mab-3 for multiple applications against pancreatic carcinomas. Antibodies (Basel) 12, 1\u201316 (2023).","journal-title":"Antibodies (Basel)"},{"key":"1797_CR130","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/0008-5472.CAN-23-0510","volume":"83","author":"Y Bei","year":"2023","unstructured":"Bei, Y. et al. Targeting CD44 variant 5 with an antibody\u2013drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma. Cancer Res 83, 2405\u20132420 (2023).","journal-title":"Cancer Res"},{"key":"1797_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534","volume":"421","author":"RL Best","year":"2021","unstructured":"Best, R. L. et al. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol 421, 115534 (2021).","journal-title":"Toxicol Appl Pharmacol"},{"key":"1797_CR132","doi-asserted-by":"publisher","first-page":"10527","DOI":"10.1021\/jm501649k","volume":"57","author":"A Maderna","year":"2014","unstructured":"Maderna, A. et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem 57, 10527\u201310543 (2014).","journal-title":"J Med Chem"},{"key":"1797_CR133","first-page":"3961S","volume":"9","author":"PK Borjesson","year":"2003","unstructured":"Borjesson, P. K. et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9, 3961S\u20133972S (2003).","journal-title":"Clin Cancer Res"},{"key":"1797_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47891-2","volume":"13","author":"ACL Mortensen","year":"2023","unstructured":"Mortensen, A. C. L. et al. Selection, characterization and in vivo evaluation of novel CD44v6-targeting antibodies for targeted molecular radiotherapy. Sci Rep 13, 20648 (2023).","journal-title":"Sci Rep"},{"key":"1797_CR135","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1182\/blood.V91.9.3401","volume":"91","author":"S Legras","year":"1998","unstructured":"Legras, S. et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 91, 3401\u20133413 (1998).","journal-title":"Blood"},{"key":"1797_CR136","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/gcc.20098","volume":"42","author":"P Liebisch","year":"2005","unstructured":"Liebisch, P. et al. Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Genes Chromosomes Cancer 42, 78\u201381 (2005).","journal-title":"Genes Chromosomes Cancer"},{"key":"1797_CR137","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24, 739\u2013748 (2018).","journal-title":"Nat Med"},{"key":"1797_CR138","first-page":"489","volume":"90","author":"P Liebisch","year":"2005","unstructured":"Liebisch, P. et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 90, 489\u2013493 (2005).","journal-title":"Haematologica"},{"key":"1797_CR139","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1182\/blood-2018-99-117974","volume":"132","author":"MG Carrabba","year":"2018","unstructured":"Carrabba, M. G. et al. Phase I\u2013IIa clinical trial to assess safety and efficacy of MLM-CAR44. 1, a CD44v6 directed CAR-T in relapsed\/refractory acute myeloid leukemia (AML) and multiple myeloma (MM). Blood 132, 5790 (2018).","journal-title":"Blood"},{"key":"1797_CR140","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fimmu.2020.00099","volume":"11","author":"S Porcellini","year":"2020","unstructured":"Porcellini, S. et al. CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice. Front Immunol 11, 99 (2020).","journal-title":"Front Immunol"},{"key":"1797_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","volume":"12","author":"L Tang","year":"2022","unstructured":"Tang, L. et al. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations. Clin Transl Med 12, e1043 (2022).","journal-title":"Clin Transl Med"},{"key":"1797_CR142","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/hum.2020.216","volume":"32","author":"A Stornaiuolo","year":"2021","unstructured":"Stornaiuolo, A. et al. Characterization and functional analysis of CD44v6.CAR T cells endowed with a new low-affinity nerve growth factor receptor-based spacer. Hum Gene Ther 32, 744\u2013760 (2021).","journal-title":"Hum Gene Ther"},{"key":"1797_CR143","doi-asserted-by":"publisher","first-page":"e1423167","DOI":"10.1080\/2162402X.2017.1423167","volume":"7","author":"V Leuci","year":"2018","unstructured":"Leuci, V. et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology 7, e1423167 (2018).","journal-title":"Oncoimmunology"},{"key":"1797_CR144","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","volume":"9","author":"M Casucci","year":"2018","unstructured":"Casucci, M. et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T Cells Co-Expressing a Suicide Gene. Front Immunol 9, 507 (2018).","journal-title":"Front Immunol"},{"key":"1797_CR145","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/neuonc\/noae144.226","volume":"26","author":"Y Zhai","year":"2024","unstructured":"Zhai, Y., Li, G., Jiang, T. & Zhang, W. P12. 13. B locoregional bi-specific CAR-T cells targeting Cd44 And Cd133 in recurrent glioblastoma: the first in-human clinical trial results. Neuro-Oncology 26, v69 (2024).","journal-title":"Neuro-Oncology"},{"key":"1797_CR146","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1158\/0008-5472.CAN-05-0207","volume":"65","author":"A Matzke","year":"2005","unstructured":"Matzke, A., Herrlich, P., Ponta, H. & Orian-Rousseau, V. A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 65, 6105\u20136110 (2005).","journal-title":"Cancer Res"},{"key":"1797_CR147","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fimmu.2015.00135","volume":"6","author":"M Finlayson","year":"2015","unstructured":"Finlayson, M. Modulation of CD44 activity by A6-peptide. Front Immunol 6, 135 (2015).","journal-title":"Front Immunol"},{"key":"1797_CR148","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1535-7163.MCT-11-0351","volume":"10","author":"RS Piotrowicz","year":"2011","unstructured":"Piotrowicz, R. S. et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther 10, 2072\u20132082 (2011).","journal-title":"Mol Cancer Ther"},{"key":"1797_CR149","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ygyno.2012.03.023","volume":"125","author":"MA Gold","year":"2012","unstructured":"Gold, M. A. et al. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125, 635\u2013639 (2012).","journal-title":"Gynecol Oncol"},{"key":"1797_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20240081","volume":"6","author":"X Pan","year":"2025","unstructured":"Pan, X. et al. Preclinical evaluation of 68Ga-labeled peptides for targeting CD44 imaging. View 6, 20240081 (2025).","journal-title":"View"},{"key":"1797_CR151","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1242\/jcs.111.11.1595","volume":"111","author":"D Peck","year":"1998","unstructured":"Peck, D. & Isacke, C. M. Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. J Cell Sci 111, 1595\u20131601 (1998).","journal-title":"J Cell Sci"},{"key":"1797_CR152","first-page":"39","volume":"1","author":"C Haiduk","year":"2013","unstructured":"Haiduk, C. et al. ADAM10 is the responsible sheddase of the CD44 ectodomain in human melanoma cells. Int J Mol Biol Biochem 1, 39\u201356 (2013).","journal-title":"Int J Mol Biol Biochem"},{"key":"1797_CR153","doi-asserted-by":"publisher","first-page":"19747","DOI":"10.1074\/jbc.M114.547273","volume":"289","author":"H Porsch","year":"2014","unstructured":"Porsch, H., Mehic, M., Olofsson, B., Heldin, P. & Heldin, C. H. Platelet-derived growth factor beta-receptor, transforming growth factor beta type I receptor, and CD44 protein modulate each other\u2019s signaling and stability. J Biol Chem 289, 19747\u201319757 (2014).","journal-title":"J Biol Chem"},{"key":"1797_CR154","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10020-022-00575-5","volume":"28","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. CD44 promotes angiogenesis in myocardial infarction through regulating plasma exosome uptake and further enhancing FGFR2 signaling transduction. Mol Med 28, 145 (2022).","journal-title":"Mol Med"},{"key":"1797_CR155","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","volume":"44","author":"H Riechelmann","year":"2008","unstructured":"Riechelmann, H. et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44, 823\u2013829 (2008).","journal-title":"Oral Oncol"},{"key":"1797_CR156","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/CAD.0b013e32801403f4","volume":"18","author":"U Rupp","year":"2007","unstructured":"Rupp, U. et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 18, 477\u2013485 (2007).","journal-title":"Anticancer Drugs"},{"key":"1797_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217541","volume":"614","author":"Y Zhai","year":"2025","unstructured":"Zhai, Y. et al. The development and potent antitumor efficacy of CD44\/CD133 dual-targeting IL7Ralpha-armored CAR-T cells against glioblastoma. Cancer Lett 614, 217541 (2025).","journal-title":"Cancer Lett"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01797-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:02:46Z","timestamp":1788339766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01797-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":157,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01797-x","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}